| Bioactivity | Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1[1]. |
| Target | ICOS/CD278, PD-1 |
| Name | Izuralimab |
| CAS | 2329669-80-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Aghanejad A, et al. A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors. Int J Biol Macromol. 2022 May 15;207:592-610. |